Literature DB >> 12078995

Pharmacokinetic-pharmacodynamic modelling of insulin: comparison of indirect pharmacodynamic response with effect-compartment link models.

Senshang Lin1, Yie W Chien.   

Abstract

The pharmacokinetic and pharmacodynamic modelling of insulin has been reported using a combined pharmacokinetic/pharmacodynamic (PK/PD) model, in which a hypothetical effect compartment is linked to a pharmacokinetic compartment. Review of the literature, however, indicated that the recently developed PK/PD models have consisted of an indirect pharmacodynamic response component, but none of them has been applied to the modelling of insulin. To study the relative relevance of the indirect pharmacodynamic response model and the effect-compartment link model in modelling the pharmacokinetics and pharmacodynamics of insulin, regular human insulin was administered intravenously at a dose of 0.1 IU kg(-1) to healthy Yucatan minipigs (after an overnight fasting). The plasma concentrations of insulin were measured by radioimmunoassay at predetermined time intervals, while blood glucose levels were monitored continuously using a glucose monitor. Analysis of the plasma insulin and the blood glucose profiles was performed by fitting with various PK/PD models and the results indicated that all of the 12 sets of plasma insulin data (after normalizing by the basal levels) have been adequately fitted to the two-compartment open pharmacokinetic model (a mean+/-s.e. correlation coefficient of 0.996+/-0.001 was obtained). The mean+/-s.e. correlation coefficient, the weighted residuals sum of squares (WRSS), and the Akaike's information criterion (AIC) were found, respectively, to be 0.935+/-0.008, 624+/-67, and 522+/-9 for the inhibitory indirect pharmacodynamic response model and 0.941+/-0.010, 547+/-63 and 513+/-9 for the stimulatory indirect pharmacodynamic response model, as compared with 0.725+/-0.041, 2309+/-276 and 628+/-10 for the effect-compartment link model. Based on these results, one may conclude that the indirect pharmacodynamic response model is a more appropriate approach for modelling the PK/PD of insulin than the effect-compartment link model.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12078995     DOI: 10.1211/0022357021779131

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  9 in total

1.  Pharmacology of intravenous insulin administration: implications for future closed-loop glycemic control by the intravenous/intravenous route.

Authors:  Nils K Skjaervold; Oddveig Lyng; Olav Spigset; Petter Aadahl
Journal:  Diabetes Technol Ther       Date:  2011-07-13       Impact factor: 6.118

Review 2.  Integrated pharmacokinetics and pharmacodynamics in drug development.

Authors:  Jasper Dingemanse; Silke Appel-Dingemanse
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

3.  Population pharmacokinetic-pharmacodynamic modeling of subcutaneous and pulmonary insulin in rats.

Authors:  Mathangi Gopalakrishnan; Sandra Suarez; Anthony J Hickey; Jogarao V S Gobburu
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-08       Impact factor: 2.745

4.  Pharmacokinetic/pharmacodynamic studies on exenatide in diabetic rats.

Authors:  Xin-gang Li; Liang Li; Xuan Zhou; Ye Chen; Yu-peng Ren; Tian-yan Zhou; Wei Lu
Journal:  Acta Pharmacol Sin       Date:  2012-06-04       Impact factor: 6.150

Review 5.  Pharmacokinetic/pharmacodynamic modelling in diabetes mellitus.

Authors:  Cornelia B Landersdorfer; William J Jusko
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

6.  Analysis of PK/PD risk factors for development of type 2 diabetes in high risk population using Bayesian analysis of glucose-insulin kinetics.

Authors:  Chih-Wei Lin; Peter Veng-Pedersen
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-09-16       Impact factor: 2.745

7.  Metallokinetic characteristics of antidiabetic bis(allixinato)oxovanadium(IV)-related complexes in the blood of rat.

Authors:  Hiroyuki Yasui; Yusuke Adachi; Akira Katoh; Hiromu Sakurai
Journal:  J Biol Inorg Chem       Date:  2007-05-15       Impact factor: 3.358

8.  Pharmacometric Approaches to Guide Dose Selection of the Novel GPR40 Agonist TAK-875 in Subjects With Type 2 Diabetes Mellitus.

Authors:  H Naik; J Lu; C Cao; M Pfister; M Vakilynejad; E Leifke
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2013-01-09

9.  Population pharmacokinetic modeling of flurbiprofen, the active metabolite of flurbiprofen axetil, in Chinese patients with postoperative pain.

Authors:  Jingru Zhang; Hong Zhang; Libo Zhao; Jian Gu; Yi Feng; Haiyan An
Journal:  J Pain Res       Date:  2018-11-30       Impact factor: 3.133

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.